Document Detail


Bismuth subsalicylate in the treatment of gastritis due to Campylobacter pylori.
MedLine Citation:
PMID:  2406863     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Fifty patients completed an investigator-blind trial comparing bismuth subsalicylate, erythromycin ethylsuccinate, and placebo matched to the bismuth salt in the treatment of gastritis associated with Campylobacter pylori. C. pylori was cleared from 14 (77.8%) of 18 patients given locally active bismuth, from one (6.7%) of 15 patients given erythromycin, and from none of 17 patients given placebo. Gastritis resolved in 13 (81%) of 16 patients treated with bismuth but in only three of 13 receiving erythromycin and in none of 16 patients given placebo. Results of endoscopic examination showed greater improvement in patients cleared of C. pylori than in those with persistent infection. Heartburn improved in 50% of patients who received bismuth compared with 17% of those given placebo. The success of bismuth is probably due to its local antimicrobial activity. Erythromycin may have been inactivated by the low pH in the areas colonized with C. pylori. Relapse is less frequent when a combination of bismuth and an antimicrobial agent is used; such a combination is characterized by local and systemic activity, stability at low pH, and good penetration into gastric mucus.
Authors:
C A McNulty
Related Documents :
3225433 - Ammonium nitrate cold pack ingestion.
8635943 - Feasibility study of the treatment of primary unresectable carcinoma of the pancreas wi...
2904423 - Fertility studies in sickle cell disease: semen analysis in adult male patients.
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Reviews of infectious diseases     Volume:  12 Suppl 1     ISSN:  0162-0886     ISO Abbreviation:  Rev. Infect. Dis.     Publication Date:    1990 Jan-Feb
Date Detail:
Created Date:  1990-03-23     Completed Date:  1990-03-23     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7905878     Medline TA:  Rev Infect Dis     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  S94-8     Citation Subset:  IM    
Affiliation:
Gloucester Public Health Laboratory, United Kingdom.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Bismuth / therapeutic use*
Campylobacter Infections / drug therapy*
Chi-Square Distribution
Erythromycin Ethylsuccinate / therapeutic use*
Female
Follow-Up Studies
Gastric Mucosa / pathology
Gastritis / drug therapy*
Gastroscopy
Humans
Male
Middle Aged
Organometallic Compounds / therapeutic use*
Randomized Controlled Trials as Topic
Salicylates / therapeutic use*
Chemical
Reg. No./Substance:
0/Organometallic Compounds; 0/Salicylates; 1264-62-6/Erythromycin Ethylsuccinate; 14882-18-9/bismuth subsalicylate; 7440-69-9/Bismuth

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Campylobacter pylori: its link to gastritis and peptic ulcer disease.
Next Document:  Epidemiology and pathophysiology of Campylobacter pylori infections.